Molecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A Protease

被引:42
|
作者
Romano, Keith P. [1 ]
Laine, Jennifer M. [1 ]
Deveau, Laura M. [1 ]
Cao, Hong [1 ]
Massi, Francesca [1 ]
Schiffer, Celia A. [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA
基金
美国国家卫生研究院;
关键词
CRYSTAL-STRUCTURE; INHIBITOR; REPLICATION; VARIANTS; CLEAVAGE;
D O I
10.1128/JVI.00377-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis C NS3/4A protease is a prime therapeutic target that is responsible for cleaving the viral polyprotein at junctions 3-4A, 4A4B, 4B5A, and 5A5B and two host cell adaptor proteins of the innate immune response, TRIF and MAVS. In this study, NS3/4A crystal structures of both host cell cleavage sites were determined and compared to the crystal structures of viral substrates. Two distinct protease conformations were observed and correlated with substrate specificity: (i) 3-4A, 4A4B, 5A5B, and MAVS, which are processed more efficiently by the protease, form extensive electrostatic networks when in complex with the protease, and (ii) TRIF and 4B5A, which contain polyproline motifs in their full-length sequences, do not form electrostatic networks in their crystal complexes. These findings provide mechanistic insights into NS3/4A substrate recognition, which may assist in a more rational approach to inhibitor design in the face of the rapid acquisition of resistance.
引用
收藏
页码:6106 / 6116
页数:11
相关论文
共 50 条
  • [21] In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
    Meeprasert, Arthitaya
    Rungrotmongkol, Thanyada
    Li, Mai Suan
    Hannongbua, Supot
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (21) : 3465 - 3477
  • [22] Hepatitis C virus NS3/4A protease blocks IL-28 production
    Ding, Qiang
    Huang, Bing
    Lu, Jie
    Liu, Yong-Jun
    Zhong, Jin
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (09) : 2374 - 2382
  • [23] Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex
    Sali, DL
    Ingram, R
    Wendel, M
    Gupta, D
    McNemar, C
    Tsarbopoulos, A
    Chen, JW
    Hong, Z
    Chase, R
    Risano, C
    Zhang, RM
    Yao, NH
    Kwong, AD
    Ramanathan, L
    Le, HV
    Weber, PC
    BIOCHEMISTRY, 1998, 37 (10) : 3392 - 3401
  • [24] Prime site binding inhibitors of a serine protease:: NS3/4A of hepatitis C virus
    Ingallinella, P
    Fattori, D
    Altamura, S
    Steinkühler, C
    Koch, U
    Cicero, D
    Bazzo, R
    Cortese, R
    Bianchi, E
    Pessi, A
    BIOCHEMISTRY, 2002, 41 (17) : 5483 - 5492
  • [25] Hepatitis C virus NS3/4A hijacks the host B-cell receptor signaling pathway
    Dai, Bojie
    Landon, Ari
    Houng, Simone
    Gartenhaus, Ronald B.
    CANCER RESEARCH, 2015, 75
  • [26] Molecular models of NS3 protease variants of the Hepatitis C virus
    da Silveira, NJF
    Arcuri, HA
    Bonalumi, CE
    de Souza, FP
    Mello, IMVGC
    Rahal, P
    Pinho, JRR
    de Azevedo, WF
    BMC STRUCTURAL BIOLOGY, 2005, 5
  • [27] Identification of Novel Small Molecule Inhibitors Against the NS3/4A Protease of Hepatitis C Virus Genotype 4a
    El-Sayed, Sara M.
    Ali, Mohamed A. M.
    El-Gendy, Bahaa El-Dien M.
    Dandash, Samar S.
    Issac, Yvette
    Saad, Reda
    Azab, Mohamed M.
    Mohamed, Mohamed R.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (37) : 4484 - 4491
  • [28] Analyzing drug-resistance in terms of substrate recognition by Hepatitis C Virus NS3 protease
    Romano, Keith
    BIOPHYSICAL JOURNAL, 2009, 96 (03) : 85A - 85A
  • [29] VANIPREVIR HCV NS3/4A Protease Inhibitor Treatment of Hepatitis C
    Hammond, E.
    Lucas, A.
    Lucas, M.
    Phillips, E.
    Gaudieri, S.
    DRUGS OF THE FUTURE, 2010, 35 (10) : 803 - 813
  • [30] Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C
    Smith, Lisa S.
    Nelson, Michael
    Naik, Sagar
    Woten, Joanna
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (05) : 639 - 648